Enliven Therapeutics Inc. (Nasdaq: ELVN), a Boulder clinical-stage precision oncology company, has enough cash on hand to fund operations into late 2026, the company disclosed this week, and through multiple milestones for two of its drug candidates.
Enliven has cash runway into late 2026 – BizWest bizwest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizwest.com Daily Mail and Mail on Sunday newspapers.
Achieved initial cumulative MMR rate of 44% by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative.
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of.
Enliven Therapeutics, Inc (ELVN) Reports Positive Proof of Concept Data from Phase 1 Trial of ELVN-001 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.